Role Definition
| Field | Value |
|---|---|
| Job Title | Medical Oncologist (BLS SOC 29-1229, Physicians All Other) |
| Seniority Level | Mid-to-Senior (5-15+ years post-fellowship) |
| Primary Function | Diagnoses and treats cancer patients using systemic therapies — chemotherapy, immunotherapy, targeted therapy, and hormone therapy. Leads multidisciplinary tumour board discussions to determine optimal treatment strategies. Manages clinical trial enrolment and oversight. Conducts goals-of-care and end-of-life conversations with patients and families. Monitors treatment toxicity and adjusts regimens. Coordinates care with surgical oncology, radiation oncology, pathology, and palliative care. |
| What This Role Is NOT | NOT a radiation oncologist (delivers radiation therapy, different fellowship — SOC 29-1224). NOT a surgical oncologist (operates to remove tumours). NOT a general internal medicine physician (broader scope, no oncology fellowship — scored at 65.5). NOT an oncology nurse (73.7) or oncology pharmacist (65.6). NOT a haematologist (though many are dual-boarded haem/onc). |
| Typical Experience | 4 years medical school (MD/DO) + 3 years internal medicine residency + 3 years medical oncology fellowship + ABIM board certification in medical oncology + state medical licence + DEA registration. 10-13+ years of training before independent practice. |
Seniority note: Seniority does not materially change the zone. All independently practising medical oncologists perform the same irreducible clinical work — treatment decisions, tumour boards, end-of-life care. Senior oncologists take on more programme leadership, research, and trial design — equally or more AI-resistant.
Protective Principles + AI Growth Correlation
| Principle | Score (0-3) | Rationale |
|---|---|---|
| Embodied Physicality | 1 | Some physical tasks — bone marrow biopsies, lumbar punctures, physical examination, lymph node palpation — but the role is primarily cognitive and consultative. Clinical environments are structured. |
| Deep Interpersonal Connection | 3 | Among the most emotionally demanding physician-patient relationships in medicine. Breaking a cancer diagnosis, navigating treatment toxicity conversations, guiding patients through goals-of-care discussions, and end-of-life care. The therapeutic relationship through a cancer journey IS the value — trust and empathy are irreducible. |
| Goal-Setting & Moral Judgment | 3 | Highest-stakes clinical judgment: deciding between curative intent and palliation, weighing survival benefit against quality of life, determining clinical trial eligibility, managing treatment toxicity trade-offs, and making the call to stop active treatment. Personal liability for every decision. |
| Protective Total | 7/9 | |
| AI Growth Correlation | 0 | AI adoption does not create or destroy oncologist demand. Demand driven by rising cancer incidence (ageing population, improved screening detection), severe workforce shortage, and global cancer burden. AI increases efficiency but cannot close the supply gap. |
Quick screen result: Protective 7/9 = Strong Green Zone signal. Proceed to confirm with task analysis.
Task Decomposition (Agentic AI Scoring)
| Task | Time % | Score (1-5) | Weighted | Aug/Disp | Rationale |
|---|---|---|---|---|---|
| Patient consultations, history, physical exam, treatment discussions | 30% | 2 | 0.60 | AUGMENTATION | AI pre-populates patient summaries, flags drug interactions, generates differential diagnoses. The oncologist still physically examines, interprets findings in clinical context, and makes treatment decisions bearing personal liability. |
| Treatment planning and tumour board participation | 20% | 2 | 0.40 | AUGMENTATION | AI tools (Tempus, Foundation Medicine) analyse genomic data and suggest matched therapies. Tumour board synthesis tools draft summaries. The oncologist integrates multidisciplinary input, weighs evidence quality, and owns the final treatment recommendation. |
| Clinical documentation and charting | 10% | 4 | 0.40 | DISPLACEMENT | Ambient AI documentation (Nuance DAX, Abridge, Suki) generates clinical notes from patient encounters. Oncologist reviews and signs. Documentation burden actively being displaced — net positive for oncologists. |
| Chemotherapy/immunotherapy management and toxicity monitoring | 15% | 2 | 0.30 | AUGMENTATION | AI assists with dosing calculations, toxicity prediction models, and adverse event flagging. The oncologist assesses patient tolerance, adjusts regimens, manages life-threatening toxicities (immune-related adverse events, neutropenic sepsis), and decides dose modifications. Licensed professional judgment required. |
| Clinical trial management and research | 10% | 3 | 0.30 | AUGMENTATION | AI trial-matching platforms (Deep 6 AI, TrialJectory) identify eligible patients 3x faster. AI assists with literature review and protocol adherence monitoring. Oncologist designs trials, determines eligibility in complex cases, manages safety oversight, and interprets results. |
| End-of-life and goals-of-care conversations | 10% | 1 | 0.10 | NOT INVOLVED | Irreducible human work. Discussing prognosis with a terminal cancer patient, navigating family dynamics around treatment withdrawal, transitioning from curative to palliative intent. Trust, empathy, and moral judgment IS the value. No AI involvement possible or desired. |
| Teaching, mentoring, administration | 5% | 3 | 0.15 | AUGMENTATION | AI assists with literature review, quality metric tracking, tumour registry submissions. Teaching fellows at the bedside and mentoring trainees through complex cases requires human oversight. |
| Total | 100% | 2.25 |
Task Resistance Score: 6.00 - 2.25 = 3.75/5.0
Displacement/Augmentation split: 10% displacement, 80% augmentation, 10% not involved.
Reinstatement check (Acemoglu): AI creates new oncologist tasks: validating AI-generated genomic therapy recommendations, interpreting AI pathology outputs (Paige AI, Valar Labs), overseeing AI-matched clinical trial enrolments, reviewing AI-flagged drug interactions in complex multi-agent regimens, and configuring clinical decision support for their patient populations. Net effect is augmentation and expanded precision medicine capability.
Evidence Score
| Dimension | Score (-2 to 2) | Evidence |
|---|---|---|
| Job Posting Trends | 2 | Severe shortage. JCO Oncology Practice projects >2,200 oncologist shortfall in 2025. Demand increased 40% from 2012-2025, supply only 25%. Median oncologist age 53, one in five over 64 — retirement wave accelerating shortfall. |
| Company Actions | 2 | No health system cutting oncologist headcount citing AI. Hospitals actively recruiting with signing bonuses and rural premiums exceeding $500K. ASCO investing in AI tools to support oncologists, not replace them. AI tools positioned as burnout mitigation (53% burnout rate, 2024). |
| Wage Trends | 2 | Average hematology/oncology salary ~$345,053 (Jan 2025). Entry-level ~$153K, mid-career ~$280K, rural premiums to $500K+. Growth outpacing inflation — reflects severe scarcity and irreplaceability. |
| AI Tool Maturity | 1 | Production tools augment oncologists: Tempus (genomic profiling), Deep 6 AI (trial matching), PathAI/Paige AI (pathology), Nuance DAX (documentation). ASCO + Google guidelines chat tool (May 2025). All require oncologist oversight. No tool can independently prescribe chemotherapy, manage toxicity, or discuss prognosis with patients. Watson for Oncology largely deprecated. |
| Expert Consensus | 2 | ESMO: AI as "copilot for treatment selection, dosing, adverse-event prediction" — not autonomous agent. McKinsey: "AI is not replacing clinicians." STAT News (Feb 2026): AI cancer tools hitting market but require oncologist oversight. Universal agreement across ASCO, ESMO, and academic literature: augmentation, not displacement. |
| Total | 9 |
Barrier Assessment
Reframed question: What prevents AI execution even when programmatically possible?
| Barrier | Score (0-2) | Rationale |
|---|---|---|
| Regulatory/Licensing | 2 | MD/DO + internal medicine residency (3 years) + medical oncology fellowship (3 years) + ABIM board certification + state medical licence + DEA registration. 10-13+ years of training. No regulatory pathway exists for AI as independent prescriber of chemotherapy. FDA classifies clinical AI as requiring physician oversight. |
| Physical Presence | 1 | Physical examination, bone marrow biopsies, and inpatient rounding require presence. Some follow-up and surveillance visits possible via telemedicine. Clinical environments are structured (clinic, hospital). Not the primary barrier. |
| Union/Collective Bargaining | 0 | Physicians are not unionised. Among the highest-compensated professionals. Not a meaningful barrier. |
| Liability/Accountability | 2 | Personal malpractice liability for chemotherapy dosing errors, missed diagnoses, treatment complications, and clinical trial patient safety. A wrong chemotherapy dose can kill. Medical boards can revoke licences. No liability framework exists for autonomous AI cancer treatment decisions. |
| Cultural/Ethical | 2 | Cancer patients fundamentally expect a human oncologist for their care journey. The physician delivering a terminal diagnosis, discussing whether to continue treatment, or guiding end-of-life decisions cannot be an algorithm. Cultural resistance to AI-only cancer care is among the strongest in any profession — cancer is deeply personal, existential, and emotionally charged. |
| Total | 7/10 |
AI Growth Correlation Check
Scored 0 (Neutral). AI adoption does not inherently create or destroy oncologist demand. Demand is driven by rising global cancer incidence (19.3 million new cases annually, projected to reach 28.4 million by 2040 per WHO), ageing demographics, and severe workforce shortage. AI tools increase oncologist efficiency — enabling faster genomic analysis, automated documentation, and improved trial matching — but the shortage is so acute that efficiency gains cannot close the gap. Not Accelerated Green — no recursive AI dependency.
JobZone Composite Score (AIJRI)
| Input | Value |
|---|---|
| Task Resistance Score | 3.75/5.0 |
| Evidence Modifier | 1.0 + (9 × 0.04) = 1.36 |
| Barrier Modifier | 1.0 + (7 × 0.02) = 1.14 |
| Growth Modifier | 1.0 + (0 × 0.05) = 1.00 |
Raw: 3.75 × 1.36 × 1.14 × 1.00 = 5.8140
JobZone Score: (5.8140 - 0.54) / 7.93 × 100 = 66.5/100
Zone: GREEN (Green ≥48, Yellow 25-47, Red <25)
Sub-Label Determination
| Metric | Value |
|---|---|
| % of task time scoring 3+ | 25% |
| AI Growth Correlation | 0 |
| Sub-label | Green (Transforming) — ≥20% task time scores 3+ |
Assessor override: None — formula score accepted.
Assessor Commentary
Score vs Reality Check
The 66.5 AIJRI places this role 18.5 points above the Green/Yellow boundary — solidly Green, not borderline. The 3.75 Task Resistance aligns with comparable physician specialties: General Internal Medicine (3.70), Family Medicine (3.75), Neurologist (3.65). The Transforming sub-label reflects real workflow change — documentation displacement (10%), clinical trial matching acceleration, and genomic analysis augmentation — while the irreducible core (treatment decisions, tumour boards, end-of-life care) remains firmly human. The label is not barrier-dependent: strip barriers entirely and AIJRI would be 57.9 — still firmly Green.
What the Numbers Don't Capture
- Supply shortage confound. The oncologist shortage (>2,200 projected shortfall, median age 53, 40% demand/25% supply growth mismatch) inflates evidence. If fellowship positions expanded dramatically or AI enabled advanced practice providers to manage more routine surveillance, evidence would soften — but the role remains Green on task analysis and barriers alone.
- Subspecialty divergence. Medical oncologists who focus primarily on clinical trials and research spend more time on AI-augmented tasks (trial matching, data analysis) — slightly more transformed. Community oncologists with heavy patient caseloads spend more time in direct care and treatment decisions — slightly more stable. Both are firmly Green.
- Cancer incidence trajectory. Rising cancer incidence (driven by ageing populations and improved detection) means demand for oncologists grows independently of any AI factor. This is a structural demand driver that the numbers capture through evidence but understate in its long-term magnitude.
Who Should Worry (and Who Shouldn't)
No mid-to-senior medical oncologist should worry about AI displacement. The "Transforming" label means daily workflow evolves — primarily documentation automation, AI-assisted genomic profiling, and accelerated trial matching — but the oncologist remains essential for every treatment decision, every tumour board, and every goals-of-care conversation. Most protected: oncologists in complex solid tumour management with heavy direct patient care, clinical trial leadership, and palliative/end-of-life work. These tasks are irreducibly human. More exposed long-term (but still Green): oncologists whose practice is primarily surveillance follow-up and routine protocol-driven chemotherapy administration — the most structured, pattern-based subset of the role. The single biggest factor: clinical judgment in ambiguous, high-stakes situations. The oncologist who integrates AI genomic tools, embraces ambient documentation, and focuses on the irreducibly human aspects of cancer care is the strongest version of this role.
What This Means
The role in 2028: Medical oncologists will use AI ambient documentation as standard (eliminating most charting burden), AI-powered genomic profiling for precision therapy selection (Tempus, Foundation Medicine), AI-assisted clinical trial matching (Deep 6, TrialJectory), and AI-augmented pathology analysis (Paige AI, Valar Labs). Documentation burden drops substantially. Treatment planning becomes faster with AI-synthesised tumour board preparation. But the oncologist still makes every chemotherapy decision, manages every toxicity crisis, leads every tumour board, and holds every end-of-life conversation.
Survival strategy:
- Adopt AI documentation and genomic profiling tools now — reclaim time from charting and accelerate precision medicine capabilities
- Develop expertise in interpreting AI-generated pathology and genomic reports — the oncologist who efficiently validates AI outputs delivers faster, more personalised care
- Lean into the irreducibly human core — complex treatment decision-making, clinical trial leadership, and the therapeutic relationship through the cancer journey
Timeline: 15-25+ years, if ever. Constrained by licensing requirements (10-13+ years of training), personal malpractice liability for chemotherapy prescribing, regulatory mandates (FDA physician oversight for clinical AI), and cultural trust (patients will not accept AI-only cancer treatment without a human oncologist).
